Black checkmark with a sparkle and a curved line underneath on a white background.
Company

INVO Fertility, Inc.

Ticker
IVF
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include revenue growth and profitability in Q2 2026, multiple reverse stock splits, and expansion of fertility services including telehealth and new therapies.

Recent developments:
  • INVO Fertility's Q2 2026 revenue increased by 17%, and the company swung to profitability during the quarter [N3].
  • The company announced and is implementing a 1-for-4 reverse stock split as of October 28, 2026 [N1].
  • INVO Fertility expanded fertility services with enhanced training and improved pricing for the INVOcell device as of July 2025 [N6].
  • The company introduced platelet-rich plasma therapy at the Wisconsin Fertility Institute to broaden treatment options [N7].
  • Telehealth services were expanded to improve access to expert fertility care across multiple states as of June 2025 [N8].
  • INVO Fertility reported a net loss of approximately $5 million in Q1 2026, with the stock reacting negatively [N4][N5].
Overview

INVO Fertility, Inc. operates in the fertility services sector, offering medical fertility treatments and devices, including the INVOcell device. The company has expanded its service offerings through telehealth and new therapies to enhance patient access and treatment options. It is publicly traded on Nasdaq under the ticker IVF and headquartered in Sarasota, Florida. The company has undergone several reverse stock splits in recent years as part of its capital structure management.

Executive summary

INVO Fertility, Inc. is a fertility services company with recent expansions in telehealth and advanced fertility treatments such as platelet-rich plasma therapy. The company reported a net loss in Q1 2026 but achieved revenue growth and profitability in Q2 2026. Multiple reverse stock splits have been implemented recently. As of September 30, 2026, the company had a current ratio of approximately 1.0 but no cash on hand. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for IVF

Bull case model:

The company has demonstrated operational improvements with revenue growth and a swing to profitability in Q2 2026. Expansion of fertility services, including telehealth and advanced therapies, may enhance market reach and patient outcomes. The issuance of patents for modified devices supports product innovation. Strategic management of capital structure through reverse stock splits indicates active financial stewardship.

Bear case model:

INVO Fertility reported net losses in recent quarters and had no cash on hand as of September 30, 2026, indicating liquidity constraints. The company faces risks related to competition, regulatory changes, and the need for continued capital to support operations and growth. Multiple reverse stock splits may reflect challenges in maintaining share price and market capitalization. Profitability remains volatile and dependent on execution of strategic initiatives.

Moat:

INVO Fertility's moat is supported by its specialized fertility treatment offerings, including proprietary devices like the INVOcell, and its expansion into telehealth services which enhance patient access. The company's focus on training and pricing improvements for its fertility devices may provide competitive differentiation. However, the fertility services market is competitive and subject to regulatory and reimbursement challenges.

Risks overview
Risks summary
Liquidity constraints combined with profitability volatility represent the most significant risks to INVO Fertility's operational stability and growth prospects.
Risks details:

• Liquidity Risk: As of September 30, 2026, the company had zero cash and cash equivalents and current liabilities slightly exceeding current assets, indicating tight liquidity conditions [S2].
• Profitability Volatility: The company reported a net loss in Q1 2026 but swung to profit in Q2 2026, showing variability in financial performance [N3][N4][S2].
• Market and Competitive Risks: The fertility services market is competitive with evolving technologies and regulatory environments that may impact operations and growth.

FINAL FORECAST FOR IVF

Final take one line
INVO Fertility shows detailed operational and financial disclosures with recent revenue growth and service expansions, balanced by liquidity and profitability challenges.
Final take 12 to 24 month view

Business trends: Expansion of fertility services including telehealth and advanced therapies; revenue growth with recent profitability swing.
Execution milestones: Implementation of multiple reverse stock splits; enhancement of INVOcell device offerings and training; broadening geographic access via telehealth.
Key risks: Liquidity constraints with zero cash on hand; profitability volatility; competitive and regulatory pressures in fertility services sector.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • INVO Fertility, Inc. is a publicly traded company on Nasdaq under the ticker IVF [S1].
  • The company operates in the fertility services sector, providing fertility-related medical services and products [N6][N7][N8].
  • INVO Fertility has expanded its fertility services by introducing platelet-rich plasma therapy at the Wisconsin Fertility Institute [N7].
  • The company has enhanced fertility services with expanded training and improved pricing for its INVOcell device [N6].
  • INVO Fertility has expanded telehealth services to improve access to expert fertility care across multiple states [N8].
  • The company reported record revenue growth in Q4 2024 and full year 2024 financial results [N6].
  • INVO Fertility reported Q1 2025 financial results with a strategic focus on core fertility operations [N6].
  • In Q1 2026, the company recorded a net loss of approximately $5 million [N4][N5].
  • In Q2 2026, INVO Fertility's revenue rose 17%, and the company swung to a profit [N3][N2].
  • The company announced and implemented multiple reverse stock splits, including a 1-for-3 split effective July 21, 2025, and a 1-for-4 split announced in October 2026 [N1][N2].
  • As of September 30, 2026, INVO Fertility reported cash and cash equivalents of $0, current assets of approximately $4.44 million, and current liabilities of approximately $4.46 million, resulting in a current ratio of about 1.0 and a cash ratio of 0 [S2].
  • The company reported a net loss of approximately $2.15 million for the quarter ending September 30, 2026, with basic and diluted EPS of -$2.44 per share [S2].
  • The company is incorporated in Nevada and headquartered in Sarasota, Florida [S1].
  • The board of directors and executive officers include CEO Steven Shum, CFO Terah Krigsvold, and Chief Business Officer Andrea Goren, among others [S1].
  • INVO Fertility has a Code of Business Conduct and Ethics applicable to all employees and directors, available on its website [S1].
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-06-12 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-10-28 | www.nasdaq.com | INVO Fertility To Implement 1-for-4 Reverse Stock Split | https://www.nasdaq.com/articles/invo-fertility-implement-1-4-reverse-stock-split
  • N2 | 2026-08-18 | www.nasdaq.com | After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day | https://www.nasdaq.com/articles/after-hours-gainers-pfsa-executes-another-reverse-split-ivf-jumps-q2-results-amlx-faces-d
  • N3 | 2026-08-17 | www.nasdaq.com | INVO Fertility Soars After Q2 Revenue Rises 17%; Swings To Profit | https://www.nasdaq.com/articles/invo-fertility-soars-after-q2-revenue-rises-17-swings-profit
  • N4 | 2026-06-23 | www.nasdaq.com | INVO Records Q1 Net Loss Of $5 Mln; Stock Down | https://www.nasdaq.com/articles/invo-records-q1-net-loss-5-mln-stock-down
  • N5 | 2026-06-22 | www.nasdaq.com | INVO Fertility, Inc. Q1 Loss Drops | https://www.nasdaq.com/articles/invo-fertility-inc-q1-loss-drops
  • N6 | 2025-07-09 | www.nasdaq.com | INVO Fertility Enhances Fertility Services with Expanded Training and Improved INVOcell Pricing | https://www.nasdaq.com/articles/invo-fertility-enhances-fertility-services-expanded-training-and-improved-invocell-pricing
  • N7 | 2025-06-30 | www.nasdaq.com | INVO Fertility Expands Fertility Services with Introduction of Platelet-Rich Plasma Therapy at Wisconsin Fertility Institute | https://www.nasdaq.com/articles/invo-fertility-expands-fertility-services-introduction-platelet-rich-plasma-therapy
  • N8 | 2025-06-18 | www.nasdaq.com | INVO Fertility Expands Telehealth Services to Enhance Access to Expert Fertility Care in Multiple States | https://www.nasdaq.com/articles/invo-fertility-expands-telehealth-services-enhance-access-expert-fertility-care-multiple
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine